Catalyst

Slingshot members are tracking this event:

GlaxoSmithKline (GSK) files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GSK

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 02, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Chronic Obstructive Pulmonary Disease, Fluticasone Furoate/umeclidinium/vilanterol